Dr. Arnd Brandenburg joined Genedata in 2005 and heads the Professional Services team of the Expressionist business unit. Before joining Genedata, Arnd worked as a theoretical physicist at DESY, Hamburg, doing research in particle physics and cosmology. He did his Ph.D. in physics at the University of Heidelberg and is a lecturer for bioinformatics and systems biology at the University of Freiburg.

Dr. Rob Burgess is currently Chief Business Officer at Sino Biological, Inc. and has over 25 years of scientific and business development experience.  His previous position was Vice President, Global Business Development at RayBiotech. Dr. Burgess holds a Ph.D. in molecular biology from the M.D. Anderson Cancer Center in Houston. 

Ross Chambers is Vice President of Antibody Discovery at Integral Molecular. He pioneered the use of DNA immunization for antibody production and developed Integral Molecular’s B-cell cloning system for antibody isolation. Before joining Integral Molecular, Dr. Chambers was Director of R&D at SDIX, where he directed the discovery of thousands of commercial antibodies.

Ryan Denomme is the CEO and co-founder of Nicoya, a biotechnology company specializing in Surface Plasmon Resonance (SPR) platforms. As a nanotech engineer and alumni of the University of Waterloo, his relentless passion to solve the challenges faced by researchers is proven by his industry-disrupting products and numerous patents. Under Ryan’s leadership, Nicoya supports hundreds of researchers at leading biotechnology and pharmaceutical organizations to accelerate their next big discovery.

Ben Doranz (President and CEO, Integral Molecular) has expertise in membrane proteins and antibodies, with 80+ publications, in journals including Cell, Science, and Nature. Dr. Doranz cofounded the company and has led all aspects of the company’s growth since its inception, bringing five different technologies from research to market.

Amanda Fitzgerald leads a team of scientific consultants at Genedata, who provide solutions for organizations with large molecule and data management needs. She received her doctorate in Biochemistry and Molecular Pharmacology from the University of Massachusetts Medical School and has pharmaceutical industry experience in biotherapeutic discovery and production groups, including scientific support for strategic alliances and development of a high-throughput protein production platform at Pfizer.

Upon finishing his studies in Pharmaceutical Sciences, Norbert pursued his interdisciplinary PhD thesis in Computational Life Sciences and Pharmaceutical Chemistry at the University of Bonn focusing on computer-aided design, synthesis, and biological evaluation of protease inhibitors. After starting his professional career at Merck KGaA as Principal Scientist, Norbert joined Sanofi in 2016 as Lab Head for Bioinformatics within the Biologics Research department. Currently Norbert is heading a section for Data Science & Computational Design to support the discovery of next generation protein therapeutics.Upon finishing his studies in Pharmaceutical Sciences, Norbert pursued his interdisciplinary PhD thesis in Computational Life Sciences and Pharmaceutical Chemistry at the University of Bonn focusing on computer-aided design, synthesis, and biological evaluation of protease inhibitors. After starting his professional career at Merck KGaA as Principal Scientist, Norbert joined Sanofi in 2016 as Lab Head for Bioinformatics within the Biologics Research department. Currently Norbert is heading a section for Data Science & Computational Design to support the discovery of next generation protein therapeutics.

Julia Gilden, PhD is a Senior Scientist at Promega Corp and specializes in the development of bioassays for immuno-oncology applications. She received her PhD in Biomedical Sciences with a focus in immunology from the University of California, San Francisco and completed postdoctoral training in cell biology and parasitology at the University of Wisconsin Madison.

John is a 24-year biotech veteran in Cell Line Development with expertise in monoclonality and single cell isolation. He also has experience ranging from cell banking and upstream process development to Discovery efforts as a Pre-Clinical Program Lead in both large pharma and CDO/CMOs.

Jake Glanville is an entrepreneur and computational immuno-engineer. He has developed multiple seminal methods in the fields of high-throughput antibody repertoire sequencing, repertoire decoding algorithms, single-cell TCR receptor & phenotype sequencing, and computationally guided antibody library engineering.

Rick led the commercial launch of the Horizon system in 2017 and the Aura system in 2020 and currently supports their ongoing commercial development by assisting customers pre and post-purchase. Prior to this, Rick held similar positions at Unchained Labs, ForteBio, and Molecular Devices. Rick holds degrees from the University of Washington and the University of Maine and has scientific training in tumor immunology and cell biology.

Larry is inventor of the AlivaMab^® Mouse, CEO and founder of Ablexis, and founder and Chairman of the Board of AlivaMab Discovery Services. He has over a quarter century of experience in creating and using transgenic mouse platforms for antibody drug discovery and development. Previously at Abgenix (now Amgen), he was an inventor and user of the XenoMouse^® technology, which has so far yielded seven approved antibody drugs.

As ATUM’s Co-Founder and CCO, Dr. Gustafsson oversees most of the company's external communications. Prior to co-founding ATUM, Dr. Gustafsson led, managed and collaborated with key strategic teams at Maxygen Inc. Before Maxygen, Dr. Gustafsson worked as a scientist at Kosan Biosciences, a number of research, teaching, and post-doctoral positions at UCs Santa Cruz and San Francisco, and at University of Umeå. He received his Ph.D. in Molecular Biology/Biochemistry from the University of Umeå, Sweden.

Michael Hantman, Associate Director of Methods Development and Validation received his Ph.D. from Temple University School of Medicine working on genetic mapping and pathogenicity of Streptococcus mutans, the main cause of dental caries.  Postdoctoral fellowships at Harvard Medical School, MGH, and the University of Washington focused on vaccine development and host-pathogen interactions, using recombinant, attenuated salmonella strains expressing heterologous genes to stimulate immune pathways.  

Adam Hejmowski is a Research Scientist working in the Gene Therapy group on chromatographic processes. He earned degrees in Biotechnology (B.S.) and Chemistry (B.S.), followed by a Masters of Science in Cellular and Molecular Biology from the University of New Haven. Previously he worked for 4 years at Abcam Inc, formerly AxioMx Inc, in Branford, CT working on monoclonal antibody development and characterization using phage display technologies and automated equipment.

Natalia Herrera did her undergraduate education studying Biochemistry at the University of California, Santa Cruz. She then went on to do her PhD. in the laboratory of Dr. Steven Almo, at Albert Einstein College of Medicine, where she studies proteins in the immunoglobin and TNFR superfamilies, and immunotherapeutics.

Kevin Heyries holds a PhD in biochemistry (Uni. of Lyon) where he developed microfluidics for antibody analysis. During his postdoctoral work (Uni. of British Columbia), he developed high throughput microfluidics systems for digital PCR and single-cell genomics. Dr. Heyries was instrumental in the development of AbCellera’s technology, where he is now leading business development and strategy.

Dr. Soraya Hölper joined Sanofi in 2017 as a Lab Head for Mass Spectrometry and works on developability and analysis of complex therapeutic antibodies. Before joining Sanofi, she helped set up the mass spectrometry platform at the Institute of Biochemistry in Frankfurt. Soraya holds a diploma degree in biochemistry from the Goethe University of Frankfurt am Main and a Ph.D. from the Max-Planck-Institute for Heart and Lung Research in Bad Nauheim.

Meredith Jackrel graduated from the College of New Jersey with a BS in Chemistry in 2004 and received her Ph.D. in Chemistry from Yale University in 2010.In 2010, Meredith joined James Shorter’s laboratory in the Department of Biochemistry and Biophysics at the University of Pennsylvania as a postdoctoral fellow. In 2017, Meredith became an Assistant Professor of Chemistry at Washington University in St. Louis. There her group studies protein misfolding and approaches to reverse misfolding.

Saurabh Joshi is the head of antibody discovery and cell-line development at Syngene. In a career spanning close to 20 years, he has worked on a wide variety of scientific challenges across therapeutic and tool antibody discovery, bio-therapeutic cell line generation, analytical tools and assay development for large molecules. Saurabh holds a PhD as well as M.Sc. from the University of Mumbai

Dr. Manzhu Kang received her Ph. D. from the University of California Los Angeles, with a dissertation focusing on the impact of combinatorial therapy on the evolution of drug resistance. Dr. Kang is a senior scientist of antibody research group at GenScript ProBio. She is in charge of the single B cell screening platform for antibody drug discovery. 

Dennis Karthaus received his master`s degree in biotechnology from the Univ. of Applied Sciences in Bremerhaven. During his thesis he worked on the development of protein purification platforms and in cell line development. In 2012, Dennis Karthaus joined IBA Lifesciences. He's leading the department for protein purification & assays and is responsible for the development of products & technologies for protein expression, purification and analysis.

Shireen S. Khan, PhD, Senior Director of Biologics at ChemPartner in South San Francisco, leads a Biologics group expanding ChemPartner’s capabilities into single B cell cloning on the Beacon platform. She also leads multiple therapeutic antibody discovery programs for biotech and pharmaceutical companies. 

Dr. Prabuddha Kundu is a Co-founder and Managing Director at Premas Biotech. He has 20 years of experience in various roles and capacities. He holds a Ph.D. in Biomedical Engineering from Indian Institute of Technology, Mumbai, and has interests in protein engineering, bio-process development, lean transformation, and new technologies. He has more than 22 publications and 10 patents. 

Dr. Lang is Vice President of Biologics at Aragen, leading antibody discovery and optimization, cell line development and protein production. Dr. Lang previously held leadership positions Genentech, Janssen and Johnson & Johnson. Dr. Lang received his Ph.D. in Molecular Microbiology from State University of New York Stony Brook.

Dr. Qingcong Lin is CEO of Biocytogen Boston Corporation, focusing on gene-targeting, humanized mouse models, RenMab/antibody discovery collaboration. Prior to joining Biocytogen, Dr. Lin was SVP of Shenogen. Prior to Sheongen, Dr. Lin led an antibody engineering group at Pfizer. Before joining Pfizer, he worked at Wyeth and Harvard Medical School as Director of Gene Modification Lab. Dr. Lin received Ph.D. from Albert-Einstein College of Medicine and completed his postdoctoral training at Harvard Medical School.

Lippy is Vice President of Research at AlivaMab Discovery Services. He has over two decades of experience in the generation and characterization of antibodies from in vivo systems.  Prior to joining AlivaMab Discovery Services, Lippy led therapeutic antibody discovery projects at Pfizer, Igenica, Ablexis and Lake Pharma. Lippy received his Ph.D. from Harvard University and did postdoctoral research at the Genomics Institute of the Novartis Research Foundation in San Diego.

Dr. Craig Magee is the Director of Business Development for the Life Science division at Daylight Solutions and is working to deliver disruptive mid-IR sensor and microscopy tools into the biomedical and pharmaceutical markets.Prior to joining Daylight, Dr. Magee worked in a variety of applications, sales and business development roles within the Life Sciences analytical and spectroscopic instrumentation sector including most recently with Protetin Simple and ThermoFisher Scientific.

Prem Swaroop Mohanty is a Life Sciences Product Specialist and Product Marketing Manager at Benchling. He holds an MBA from UC Berkeley, a MS from U of Illinois, Chicago, and a B.Pharm from U of Mumbai. He has over 13 years of industry experience across biopharma R&D, strategy consulting, and software product marketing. Prior to Benchling, Prem was a Sr. Consultant at Navigant, a Scientist at Allergan, and Research Scientist at deCODE.

Prem Swaroop Mohanty is a Life Sciences Product Specialist and Product Marketing Manager at Benchling. He holds an MBA from UC Berkeley, a MS from U of Illinois, Chicago, and a B.Pharm from U of Mumbai. He has over 13 years of industry experience across biopharma R&D, strategy consulting, and software product marketing. Prior to Benchling, Prem was a Sr. Consultant at Navigant, a Scientist at Allergan, and Research Scientist at deCODE.

Nicholas Morano did his undergraduate education studying Biochemistry at Binghamton University. He then went on to do his PhD. in the laboratory of Dr. Steven Almo, at Albert Einstein College of Medicine, where he studies the structure and function of interactions between the immunoglobin and TNFR superfamilies.

With over 10 years of experience in the membrane proteins field, Dr. Rony Nehmé has a deep and solid understanding of GPCRs biology, pharmacology and structural studies. He was an Investigator Scientist in the lab of Prof. Chris Tate (MRC-LMB in Cambridge) prior to joining Creoptix in 2018 as an Application Scientist. He holds a PhD in molecular biology from the Université de Nice-Sophia Antipolis in France.

Dr. Owen is an Assistant Professor in the Pharmaceutical Chemistry department at the University of Utah. He is also an Adjunct Assistant Professor in the Internal Medicine, Bioengineering, and Medicinal Chemistry Departments. His lab utilizes protein engineering and bioconjugation techniques in developing therapeutic and diagnostic platforms to enable precision medicine.

Dr. Alison Porter first joined Lonza in 1998 where she spent 13 years working in the Cell Culture Process Development Group. In 2011, she joined Fujifilm Diosynth Biotechnologies as Head of the Mammalian Cell Culture R&D Department and led the development of the company’s mammalian expression platform. Alison re-joined Lonza in 2016 as Head of Process Development Sciences. She now serves as the Head of Expression System Sciences where she provides in-depth scientific and technical leadership to those working with Lonza’s GS Gene Expression System^®.  Alison specialises in expression systems and the construction of recombinant cell lines. She has a Ph.D. in Biotechnology from the University of Manchester.

Dr. Sandig is recognized for seminal fundamental and applied research in cell and vector biotechnology, and the development of innovative vaccine technologies. Notably, for instigating and developing the cell-line development program at ProBioGen AG, which resulted in one of the leading CHO platforms, the co-development of the CHO-Freedom Kit with LTC (now Thermo-Fisher), and the development of glycoengineering technologies, and notably GlymaxX at ProBioGen.

Aaron is CSO of the Biopharma Vertical at Twist Bioscience.  Prior to Twist, he served as Chief Scientific Officer of LakePharma, leading the California Antibody Center, which discovers novel antibody therapeutics for its clients. He also oversaw all discovery research functions both as Vice President of Protein Sciences at Surrozen, and previously, as Vice President of Research at Sutro Biopharma, Inc. He also held director level positions at both Oncomed and Dyax Corp.

Stephanie earned her Ph.D. in Biochemistry from Washington University in St. Louis, where she used neuronal cell models to discover and interrogate novel signaling pathways that regulate neurite structure.  As a Senior Scientist, she used precision genome engineering technologies, such as CRISPR/Cas9, to create cellular models for use in drug and cell therapy research and development.  Stephanie is currently a Principal Scientist at MilliporeSigma and leads a team of Cell Design Studio scientists.

Basile is a trained viral immunologist with a Ph.D. from the TU Munich, Germany. After a brief antibody engineering related stint at Roche Diagnostics, he pursued a post-doctoral fellowship at LUMC in Chicago, followed by a five year infectious diseases junior faculty tenure at RUMC also in Chicago. Over the last 6 years, Basile held various field positions as Field Application Scientist, Market Development Scientist and in Business Development.

Noel completed his PhD and subsequent post-doctoral studies at the University of Cambridge in the field of metabolic disease. Noel joined Lonza in 2009 and was involved in the setup of the human primary cell-based assay platform and now Heads the Immunology group which develops assays to screen products for immunogenicity and immunotoxicity risk. The Lonza Cambridge site is focused on the development and provision of services to support the development of new biotherapeutic proteins and vaccines with a particular focus on immunogenicity, immunotoxicity, manufacturability and protein expression.

After his PhD in Cell and Molecular Biology from Texas A&M, Colby joined MassBiologics. There, he led programs to discover and advance mAbs for the prevention, treatment or diagnosis of infectious and endogenous diseases. He later joined the Kanyos Bio Protein Engineering team to develop therapeutics based on a novel antigen-specific immune tolerance platform. Colby joined Abveris Antibody as Chief Scientific Officer to usher in new antibody discovery tools and build a premium discovery engine. 

Anthony is leading BD at Rapid Novor where he has merged his training in biomedical engineering with his passion for research. He's focused on helping pharma and biotech companies leverage REpAb to sequence mAbs from polyclonal sera in patients or animal models, as well as immune system profiling using NovorIg. 

Lars Stöckl joined Glycotope in 2005 and besides other tasks was responsible for the establishment of the GlycoExpress plattform and for setting up the glyco-analytical lab. Since January 2020 he heads the service department of Glycotope.

Before the appointment at Glycotope he gained experience in cell line engineering and protein chemistry during his PhD and Postdoc at the Robert Koch-Institute /Berlin, the Charite / Berlin and the Breakthrough Breast Cancer Research / London.

Sean is working as as Manager of Field Application Scientist. He has over sixteen years of research, scientific writing and collaborative experience with the life scientists. He has worked as Field Application Scientist in Bio-Rad for several years. He holds a Ph.D of Biology and a Masters of Business Administration from McGill University, Montreal. He completed his undergraduate studies in Biochemistry at the Institute for Cooperative Education, Concordia University, Montreal.

Michael brings an extensive knowledge and expertise in molecular genetics, signal transduction, and cell engineering and is the inventor of the iLite™ reporter gene technology. Michael is the author of more than 200 articles on cytokines, biotechnology, and immunogenicity. 

Dr. Birgit Viira is a Key Account and Technology Officer at Icosagen.